---
title: "Harmony Biosciences | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 239 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262433821.md"
published_at: "2025-10-23T12:16:12.000Z"
---

# Harmony Biosciences | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 239 M

Revenue: As of FY2025 Q3, the actual value is USD 239 M, beating the estimate of USD 220.04 M.

### Financial Metrics

#### Segment Revenue

-   WAKIX® (pitolisant) franchise delivered net revenue of approximately $239 million in Q3 2025, representing a 29% year-over-year revenue growth.

#### Operational Metrics

The reference does not provide specific operational metrics such as net income, gross margin, operating profit, operating margin, or operating costs for the third quarter of 2025.

#### Cash Flow

There is no information provided regarding operating cash flow or free cash flow in the reference text.

#### Unique Metrics

No unique company-specific financial indicators are mentioned in the reference text.

### Outlook / Guidance

-   Harmony Biosciences has increased its 2025 revenue guidance to $845-$865 million from the previous range of $820-$860 million.
-   The company anticipates continued growth and market opportunity for WAKIX, positioning it towards potential blockbuster status in narcolepsy treatment.
-   Full Q3 2025 earnings will be reported on November 4th, 2025, with a conference call scheduled to discuss the results.

### Related Stocks

- [HRMY.US - Harmony Biosciences](https://longbridge.com/en/quote/HRMY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 14:57 ETQvinci and Harmonyze Announce Strategic Partnership to Elevate Franchise Performance Coaching | Qvinci Software and Harmonyze have announced a strategic partnership aimed at enhancing franchise performance coaching.  | [Link](https://longbridge.com/en/news/275651785.md) |
| Sandip Kapadia Sells 3,746 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock | CFO Sandip Kapadia of Harmony Biosciences sold 3,746 shares at $37.15 each, totaling $139,163.90, reducing his ownership | [Link](https://longbridge.com/en/news/274076411.md) |
| Assessing Harmony Biosciences (HRMY) Valuation As Growth, Financial Strength And Technical Signals Attract Investors | Harmony Biosciences (HRMY) is attracting investor interest due to its revenue and earnings growth, solid financial posit | [Link](https://longbridge.com/en/news/273826298.md) |
| Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares | Sandip Kapadia, CFO of Harmony Biosciences Holdings Inc., reported the disposal of common shares of the company. The ful | [Link](https://longbridge.com/en/news/274069011.md) |
| Harmony Biosciences CFO Sells Over 20K Shares | Harmony Biosciences CFO Sandip Kapadia sold 20,961 shares of common stock on January 15, 2026, at a weighted average pri | [Link](https://longbridge.com/en/news/273157191.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.